176 related articles for article (PubMed ID: 23619284)
21. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
[TBL] [Abstract][Full Text] [Related]
22. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Wang F; Mi YJ; Chen XG; Wu XP; Liu Z; Chen SP; Liang YJ; Cheng C; To KK; Fu LW
Mol Med; 2012 Jul; 18(1):887-98. PubMed ID: 22549112
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitors enhance ciprofloxacin-induced phototoxicity by inhibiting ABCG2.
Mealey KL; Dassanayake S; Burke NS
Oncology; 2014; 87(6):364-70. PubMed ID: 25227759
[TBL] [Abstract][Full Text] [Related]
24. ABCG2: the key to chemoresistance in cancer stem cells?
An Y; Ongkeko WM
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1529-42. PubMed ID: 19708828
[TBL] [Abstract][Full Text] [Related]
25. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
26. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
27. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Zhang H; Zhang YK; Wang YJ; Kathawala RJ; Patel A; Zhu H; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Fu LW
Cancer Sci; 2014 Aug; 105(8):1071-8. PubMed ID: 24903205
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
30. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
31. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
32. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
[TBL] [Abstract][Full Text] [Related]
34. Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
Zhang GN; Zhang YK; Wang YJ; Barbuti AM; Zhu XJ; Yu XY; Wen AW; Wurpel JND; Chen ZS
Pharmacol Res; 2017 May; 119():89-98. PubMed ID: 28131876
[TBL] [Abstract][Full Text] [Related]
35. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
36. The dopamine D
Hussein N; Amawi H; Karthikeyan C; Hall FS; Mittal R; Trivedi P; Ashby CR; Tiwari AK
Cancer Lett; 2017 Jun; 396():167-180. PubMed ID: 28323029
[TBL] [Abstract][Full Text] [Related]
37. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Shi Z; Tiwari AK; Shukla S; Robey RW; Singh S; Kim IW; Bates SE; Peng X; Abraham I; Ambudkar SV; Talele TT; Fu LW; Chen ZS
Cancer Res; 2011 Apr; 71(8):3029-41. PubMed ID: 21402712
[TBL] [Abstract][Full Text] [Related]
38. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
39. Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Wang XK; He JH; Xu JH; Ye S; Wang F; Zhang H; Huang ZC; To KK; Fu LW
Cancer Res; 2014 Aug; 74(16):4431-45. PubMed ID: 24972892
[TBL] [Abstract][Full Text] [Related]
40. Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10).
Deng W; Dai CL; Chen JJ; Kathawala RJ; Sun YL; Chen HF; Fu LW; Chen ZS
Oncol Rep; 2013 Jun; 29(6):2479-85. PubMed ID: 23525656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]